Press Release - Company Data

Oculus Innovative Sciences to Create Subsidiary for Company's Anti-Infective Drug Assets
Posted 2012-11-26 00:23NAI Editing
today announced it has initiated the process to create a wholly owned subsidiary that will hold the company's anti-infective drug assets.

Oculus Innovative Sciences Completes Patient Enrollment in Study of Microcyn(R) Hydrogel in Management of Scars
Posted 2012-11-14 00:19NAI Editing
today announced it has completed patient enrollment in its double-blind, randomized clinical study evaluating an advanced Microcyn® hydrogel for management of hypertrophic and keloid scars under an F

Oculus Innovative Sciences Achieves Net Worth of $4.5 Million Pro Forma as of September 30, 2012 and Regains Compliance with the Stockholders' Requirement of the NASDAQ Listing Rules
Posted 2012-11-04 23:52NAI Editing
As previously announced, on May 21, 2012, Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences Reports Record Revenues of $4.5 Million for the Second Quarter of Fiscal 2013
Posted 2012-11-01 06:17NAI Editing
today announced financial results for the second quarter of fiscal year 2013, ended September 30, 2012.

Oculus Innovative Sciences Announces Results From Study of Microcyn(R) Technology-Based Atrapro(TM) Antipruritic Hydrogel Used in Combination With Neosalus(R) Cream in Treatment of Atopic Dermatitis
Posted 2012-10-08 23:07NAI Editing
today announced results of a multicenter, prospective and open-label pilot study in which Microcyn® Technology-based Atrapro™ Antipruritic Hydrogel was evaluated in combination with Neosalus

Oculus Innovative Sciences Announces Publication of Results From Study of Microcyn(R) Technology-Based Antipruritic Hydrogel in Treatment of Atopic Dermatitis
Posted 2012-09-26 23:05NAI Editing
today announced publication of an open-label pilot study in which a Microcyn® Technology-based antipruritic hydrogel was evaluated in the treatment of atopic dermatitis.

Oculus Innovative Sciences Updates Guidance: Faster Path to Positive EBITDAS as Result of Recent Partnership
Posted 2012-09-19 23:04NAI Editing
a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products, today announced the finalization of transition of marketing and sales to More Pha

Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Prevention and Treatment of Peritonitis With Microcyn(R) Technology
Posted 2012-09-10 23:11NAI Editing
a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products, today announced the issuance of new U.S.

Oculus Innovative Sciences Receives $5.1 Million Licensing Fee From More Pharma
Posted 2012-09-06 00:39NAI Editing
innovator and developer of products based upon the Microcyn® Technology platform, announced today that the company has received payment of $5.1 million per the licensing agreement executed on August

Oculus Innovative Sciences Enrolls First Patient in Study of Microcyn(R) Hydrogel in Management of Scars
Posted 2012-08-16 00:31NAI Editing
today announced it has enrolled the first patients in its double-blind, randomized clinical study evaluating an advanced Microcyn® hydrogel for management of hypertrophic or keloid scars under an FDA